Article
In this environment, the traditional chief legal officer (CLO) model for IDNs and health systems, often oriented around compliance and defense, has reached its limit. Amid rapid technological change and mounting competitive pressure, the evolution of health system legal leadership is accelerating. Over the next decade and beyond, the CLO must grow into a true strategic enterprise driver.
Historically, the CLO’s remit reflected the standard vertically integrated, fee-for-service operating model. The focus was regulatory adherence, litigation avoidance, and internal controls. That model assumed relatively clear organizational boundaries. Healthcare today is networked, not closed, and legal risk now travels through partnerships and shared platforms. IDNs rely on:
AI operates across all of it – diagnostics, utilization management, population health, contracting, and patient engagement. Legal leadership must therefore serve not only as institutional protector but also ecosystem architect. The mandate is shifting to not simply mitigating risk, but designing governance structures that allow the safe scaling of innovation and collaboration. The real differentiator for CLOs now lies in commercial fluency, partnership design, and the ability to manage risk across both human- and machine-driven systems.
Three areas in particular are redefining the job.
Health systems are entering multi-party alliances and co-developing AI-enabled products with technology firms, life sciences companies, and payers. These are no longer traditional vendor relationships – they’re shared-risk, shared-reward ventures. Accordingly, the CLO must structure governance around:
Importantly, AI isn’t just an operational tool; it’s embedded in contracts, shared platforms and clinical workflows. Legal leadership will be expected to ensure that speed to market does not outpace governance that is compliant, documented, and able to withstand regulatory and litigation scrutiny.
As value-based care becomes more prominent, IDNs are assuming greater financial and clinical risk, moving from fee-for-service reimbursement toward shared savings, downside risk and population health accountability. In this environment, AI increasingly shapes provider accountability, quality measurement, cost forecasting, and utilization management. Legal risk is no longer confined to financial exposure; it now includes uncontrolled model variability, data bias, regulatory scrutiny, and reputational consequences. The CLO becomes a critical partner to finance, actuarial, and clinical leaders, ensuring that contracts anticipate model variability, define performance accountability, and guard against unintended inequities.
Addressing social determinants of health requires collaboration with nonprofit and community partners. These contexts can amplify issues of fairness, consent, data provenance and reputational exposure, and governance has to be especially rigorous when automated decision tools affect vulnerable populations. Predictive analytics and AI-driven targeting can improve identification of need and resource allocation in these partnerships, but they also heighten risks related to bias, transparency, and data stewardship, making that rigorous governance essential. Amid all of this, the CLO becomes a steward of trust, establishing ethical guardrails that protect patients, partners, and the enterprise.
This ongoing evolution requires a shift in how boards and management teams evaluate legal leaders. Technical expertise and tenure won’t be enough. The next-generation CLO instead indexes high on:
The strongest chief legal officers will be able to translate technical and algorithmic risk into clear executive choices about risk tolerance, investment, and operational design. They don’t simply interpret regulation; they shape enterprise strategy within it. They’ll make critical assessments, such as asking “Where are the real partnership exposures? How much value-based risk is sitting in existing contracts? How mature is our organization’s AI governance and data handling – in reality, not just on paper?”
The enterprise moves faster and more confidently when the CLO is brought in early to strategy, innovation, and technology conversations. If not, legal reacts rather than shapes. In many IDNs, the CLO is quietly becoming one of the most strategic leaders at the table. Not because regulation is expanding (although it is), but because growth, partnerships, AI deployment, and risk-bearing economics are now inseparable.
Boards and management teams don’t need a more cautious lawyer. They need a legal leader who can help the organization move forward without stepping into avoidable risk.
The focus of legal leadership today will show up over time – in the quality of partnerships, the durability of contracts, the trust of regulators, and ultimately in enterprise performance.
Sarah Eames leads the Russell Reynolds Associates’ Healthcare Services practice. She is based in New York.
Amy Saddington leads Russell Reynolds Associates’ Healthcare Services and Digital Health North American Practices. She is based in Dallas.
Casey Gordon co-leads Russell Reynolds Associates' Legal, Regulatory, and Compliance Practice in the Americas. She is based in Chicago.
Olivia Floto leads Commercial Strategy & Insights for Russell Reynolds Associates’ Healthcare Services Practice. She is based in Chicago.
ja-JP
ログイン
